Human adipose stem cell-derived exosomes and methods of treating parkinson's disease

The administration of exosomes from human adipose-derived stem cells addresses the limitations of current Parkinson’s disease treatments by protecting neurons and modulating inflammatory responses, providing a potential therapeutic avenue to slow disease progression and preserve motor function.

WO2024186658A9PCT designated stage expired Publication Date: 2024-11-14THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/018154
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-03
Filing Date
2024-03-01
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current treatments for Parkinson’s disease are limited in effectively slowing or stopping disease progression and are associated with significant side effects, with no clinically effective avenue for curing the disease complex, and there is a need for therapeutic strategies that target the underlying disease mechanisms rather than just symptom relief.

Method used

Administration of exosomes isolated from human adipose-derived stem cells (hASCs), which are shown to protect neurons, reduce dopaminergic cell loss, and modulate inflammatory responses in the substantia nigra, thereby addressing the disease’s neurodegenerative processes.

Benefits of technology

The use of hASC exosomes demonstrates potential in reducing neurodegeneration, preserving dopaminergic neurons, and modifying microglial activation, offering a promising therapeutic approach to slow Parkinson’s disease progression and improve motor function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024018154_14112024_PF_FP_ABST
    Figure US2024018154_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to compositions comprising exosomes isolated from human adipose-derived stem cells and their use in a method of treating or preventing Parkinson's disease in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

HUMAN ADIPOSE STEM CELL-DERIVED EXOSOMES AND METHODS OF TREATING PARKINSON’S DISEASECROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 449,619, filed March 3, 2023, which is incorporated by reference herein in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0002] This invention was made with government support under grant numbers I01BX000231 and IK6BX004214 awarded by Department of Veterans Affairs. The government has certain rights in the invention.BACKGROUND

[0003] Idiopathic Parkinson's disease (PD), the second most common movement disorder, is characterized by massive and progressive loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) with accompanying, severe motor symptoms, including tremor, bradykinesia, rigidity and postural instability (Bennett et al., 1996; Ball, 2001). Fifty percent of individuals over the age of 80 are affected by age-related PD (Bennett et al., 1996). Research suggests that a combination of environmental and genetic factors play a role in this disease complex, but optimal animal models for this combined etiology have not been developed until recently. Despite reported success with neurotrophic or neuroprotective therapeutic drugs or cell replacement therapies in animal models of PD, none have led to a clinically effective treatment avenue for curing the complete disease complex (Toulouse, 2008). Since aging appears to be the number one risk factor for PD, a need exist for designing appropriate animal models.

[0004] Treatments for slowing or stopping the progression of PD are limited to surgery, lifestyle changes, and a few medications that replace the lost dopamine but they do not treat the disease itself. Current FDA approved therapeutics for PD do not affect the disease progression, and their use is limited because these treatments decrease the ability to improve symptoms over time and also lead to side effects that become problematic. Thus, a need also exists for therapeutic strategies that are targeted to slowing or stopping the progression of the disease with an improved adverse effect profile.BRIEF SUMMARY

[0005] Disclosed herein are compositions comprising human adipose-derived stem cells (hASCs) and methods of using the same.

[0006] Disclosed herein are methods of treating Parkinson’s disease in a subject, the methods comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs).

[0007] Disclosed herein are methods of preventing Parkinson’s disease in a subject, the methods comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs).

[0008] Disclosed herein are methods of protecting neurons from cell death in a subject with or at risk for developing Parkinson’s disease, the methods comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs).

[0009] Disclosed herein are methods of reducing or preventing dopaminergic cell loss in the substantia nigra pars compacta in a subject, the methods comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs).

[0010] Disclosed herein are methods of reducing to preventing loss of tyrosine hydroxylase in a subject, the methods comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs).

[0011] Disclosed herein are methods of reducing MHCII expression in a subject, the methods comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs).

[0012] Disclosed herein are methods of increasing pro-inflammatory signaling in the ILip pathway and the NFKB pathway in a subject, the methods comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs).

[0013] Disclosed herein are methods of reducing the amount of TNFoc secreted in microglia in a subject, the methods comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs).

[0014] Disclosed herein are methods of reducing microglial activation in the substantia nigra in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs).BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIGS. 1A-D show that consumption of an astaxanthin (AXT) enriched diet attenuates the loss of TH positive neurons in the substantia nigra pars compacta in young mice (FIGS. 1A, AB) while aged animals do not demonstrate any protection against MPTP induced neurodegeneration (FIGS. 1C, AD). A bar graph shows the stereological quantification of TH positive neurons in the SNpc in young (FIG. 1A) and C) aged mice (FIG. 1C). Data is represented as mean + SEM. Immunohistochemistry with anti-TH antibody in the SNpc of young (FIG. IB) and aged mice (FIG. ID). Two-way ANOVA; Young: p<0.05: Diet effect: p<0.01 DF: (1,19) F: 8.65; Bonferroni post hoc: *p<0.1; 2 tailed T test: **p<0.01 Aged: not significant; DF: (1,11) F: 1.03; Bonferroni post hoc: ** p<0.01 : 2 tailed T tests: **p<0.01 ***p<0.001. Scale = 200 pm

[0016] FIGS. 2A-C show that AXT supplementation decreases MPTP induced microglial activation in the SNpc in young but not aged mice. FIG. 2A shows representative immunohistochemistry depicting cells that were categorized as activated in both young and aged animals. A bar graph shows the estimated population of activated microglia cells in the SNpc of young (FIG. 2B) and aged mice (FIG. 2C). Data is represented as mean + SEM. aged mice. 2 way ANOVA: Young: *p<0.05, DF: (1, 18) F: 7.03: 2 tailed T test: ***p<0.001; Aged: not significant, DF: (1,26) F: 0.01; 2 tailed T tests: *p<0.05, ***p<0.001.

[0017] FIGS. 3A-C show that age alters primary microglia response to pro- and antiinflammatory cytokines. FIG. 3A depicts RTqPCR analysis of primary microglia shows increased pro-inflammatory gene expression at baseline. FIG. 3B shows that primary microglia stimulated with 20 ng / ml TNFa for 24 hours. Aged cells had significantly higher levels of ILip,IL6, and Marco. FIG. 3C shows young and old primary microglia treated with 20 ng / ml IL4 for 24 hours. Aged microglia exhibited lower expression of IGF1, and Fizz genes.

[0018] FIGS. 4A-C depicted genes driving the prediction of an upregulation of IL11 following CCI. The numbers below the genes indicate actual fold change from control in (FIG. 4A) TBI (C vs T), (FIG. 4B) TBI with hASC exosomes (C vs TE) and (FIG. 4C) TBI with hASC exosomes depleted of MALAT1 (C vs TEdM). Red indicates down-regulation, green indicates up-regulation. The darker the color the higher the fold change. Observed that in (FIG. 4B) there is a significant change in gene expression indicating a lower activation of IL11 resulting from the exosome treatment. This was not observed with exosomes depleted of MALAT1 (FIG. 4C).

[0019] FIGS. 5A-E show hASC exosomes protect neurons for injury. FIG. 5A shows HT22 cells were treated with lOOpM H2O2 for 24 hours, followed by treating cells either with 2 ng hASC exosomes (exo) or MALAT1 depleted exosomes (exo - Ml) for an additional 24 hours. The number of Ki67 cells per 10X field were counted in 5 fields per well. The experiment was run in triplicate with 4 biological replicates. The results show that hASC exosomes protected HT22 cells from H2O2 injury. A scratch assay was also performed to assess proliferation of cells. FIG. 5B shows that hASC exosomes significantly increased the proliferation and migration of the HT22 cells in the cell free zone. Representative images are shown in FIGS. 5C - D. In both assays, hASC exosomes depleted of MALAT1 had significantly reduced efficacy demonstrating an importance of MALAT1 in the efficacy of the hASC exosomes.

[0020] FIG. 6 shows bar graphs demonstrating that treatment with hASC exosomes at two weeks post rAAV9-SYN injection into the SN prevents loss of TH and reduces the expression of MHCII. N = 5 rats per group. Both of these changes were found to be significantly different between AAV9-Syn and AAV9-Syn treated with hASC exosomes (p<0.095 two-tailed students t-test).

[0021] FIG. 7 shows SH-SY5Y cells were differentiated and then exposed to aggregated WT synuclein or H2O2 for 2 hours followed by treatment with hASCexo (Ipg / ml) and an MTT assay was performed at 24 hours. There was significant loss of cells following both a-syn and H2O2 treatment that was protected by hASC exosome addition.

[0022] FIG. 8 shows the timeline of the experimental design. Prior to rAAV9-Syn injection, baseline paw preference was observed and tested again weeks 4 and 8 after injection. At week 3, rats received either a dose of exosomes or PBS. IHC was conducted at week 9.

[0023] FIG. 9 shows the percent paw touch at three different time points.

[0024] FIG. 10 shows that exosomes rescued dopaminergic neurons in the substantia nigra (SN) pars compacta.

[0025] FIGS. 11 A-D show representative photomicrographs of tyrosine hydroxylase (TH) staining (marker for dopamine neurons) in the substantia nigra pars compacta. FIG. 11 A shows mKate (control). FIG. 1 IB shows rAAV9-syn injection and treated with PBS. FIG. 11C shows rAAV9-syn injection and treated with 60 pg of exosomes. FIG. 1 ID shows rAAV9-syn injection and treated with 100 pg of exosomes.

[0026] FIG. 12 shows that treatment with exosomes reduces microglia upregulation of MHCII in the substantia nigra (SN). mean±SEM. One-way ANOVA followed by post-hocs *p<0.05.

[0027] FIG. 13 shows the timeline of experimental design. Prior to rAAV9-Syn injection, baseline paw preference was observed and tested again weeks 4 and 8 after injection. At week 3, rats received either a dose of exosomes or PBS. IHC or scRNA seq was conducted at week 8.

[0028] FIGS. 14A-E show representative photomicrographs of tyrosine hydroxylase (TH) staining (marker for dopamine neurons) in the substantia nigra pars compacta (SNpc). FIG. 14A shows mKate (control). FIG. 14B shows rAAV9-syn injection and treated with PBS. FIG. 14C shows rAAV9-syn injection and treated with 60pg of exosomes. FIG. 14D shows rAAV9-syn injection and treated with lOOpg of exosomes. FIG. 14E shows the percent area of positive cells in SNpc. Significant difference between Syn+ExolOO and Syn+PBS. Significant difference between mKate and Syn+PBS mean ±SEM. One Way ANOVA followed by post-hocs. *p<0.05;** p<0.01.

[0029] FIG. 15 shows distinct clusters identified in treatment and experimental groups.

[0030] FIGS. 16A-B show gene biological process ontology of cluster A (FIG. 16A) and B (FIG. 16B).DETAILED DESCRIPTION

[0031] The disclosed method and compositions may be understood more readily by reference to the following detailed description of particular embodiments and the Example included therein and to the Figures and their previous and following description.

[0032] It is to be understood that the disclosed method and compositions are not limited to specific synthetic methods, specific analytical techniques, or to particular reagents unless otherwise specified, and, as such, may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0033] Disclosed are materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed method and compositions. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited, each is individually and collectively contemplated. Thus, is this example, each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Likewise, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment orcombination of embodiments of the disclosed methods, and that each such combination is specifically contemplated and should be considered disclosed.Definitions

[0034] It is understood that the disclosed method and compositions are not limited to the particular methodology, protocols, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0035] It must be noted that as used herein and in the appended claims, the singular forms “a “, “an”, and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “an adipose stem cell exosome” includes a plurality of such adipose stem cell exosomes, reference to "the composition" is a reference to one or more compositions and equivalents thereof known to those skilled in the art, and so forth.

[0036] As used herein, the term “subject” or “patient” can be used interchangeably and refer to any organism to which a composition of this invention may be administered, e.g., for experimental, diagnostic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as non-human primates, and humans; avians; domestic household or farm animals such as cats, dogs, sheep, goats, cattle, horses and pigs; laboratory animals such as mice, rats and guinea pigs; rabbits; fish; reptiles; zoo and wild animals). Typically, “subjects” are animals, including mammals such as humans and primates; and the like.

[0037] By “ treat” is meant to administer a composition of the invention to a subject, such as a human or other mammal (for example, an animal model), that has, for example, Parkinson’s disease or a disease associated with dopaminergic cell loss.

[0038] As used herein, the terms “administering” and “administration” refer to any method of providing a disclosed composition to a subject. Such methods are well known to those skilled in the art and include, but are not limited to: oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration,rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition. In further various aspects, a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition. In an aspect, the skilled person can determine an efficacious dose, an efficacious schedule, or an efficacious route of administration for a disclosed composition or a disclosed protein so as to treat a subject or induce an immune response. In an aspect, the skilled person can also alter or modify an aspect of an administering step so as to improve efficacy of a disclosed composition. Multiple doses of the composition can be administered. The frequency and duration of administration of the composition can vary, depending on any of a variety of factors, including patient response, etc.

[0039] A “therapeutically effective amount,” or “effective dosage” or “effective amount” as used interchangeably herein unless otherwise defined, means a dosage of a drug effective for periods of time necessary, to achieve the desired therapeutic result.

[0040] In accordance with the present invention, a suitable single dose size is a dose that is capable of preventing or alleviating a symptom in a subject when administered one or more times over a suitable time period. An effective dosage can be determined by a person skilled in the art and can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the drug to elicit a de-sired response in the individual. Therapeutically effective amounts for the disclosed compositions comprising hASC exosomes can be readily determined by those of ordinary skill in the art.

[0041] A therapeutically effective amount may be administered in one or more administrations (e.g., the compositions comprising hASC exosomes can be given as a preventative treatment or therapeutically at any stage of disease, before or after symptoms, and the like), applications or dosages and is not intended to be limited to a particular formulation, combination or administration route. It is within the scope of the present disclosure that the disclosed compositions comprising hASC exosomes can be administered at various times duringthe course of treatment of the subject. The times of administration and dosages used will depend on several factors, such as the disease state, age, sex, and weight of the individual, and the ability of the composition to elicit a desired response in the individual. Administration can be adjusted according to individual need and professional judgment of a person administrating or supervising the administration of the compounds used in the present invention.

[0042] “Optional” or “optionally” means that the subsequently described event, circumstance, or material may or may not occur or be present, and that the description includes instances where the event, circumstance, or material occurs or is present and instances where it does not occur or is not present.

[0043] A “pharmaceutically acceptable excipient,” “pharmaceutically acceptable diluent,” “pharmaceutically acceptable carrier,” or “pharmaceutically acceptable adjuvant” as used herein means an excipient, diluent, carrier, and / or adjuvant that are useful in preparing a pharmaceutical composition that are generally safe, non-toxic and neither biologically nor otherwise undesirable, and include an excipient, diluent, carrier, and adjuvant that are acceptable for veterinary use and / or human pharmaceutical use, such as those promulgated by the United States Food and Drug Administration.

[0044] Ranges may be expressed herein as from “about” one particular value, and / or to “about” another particular value. When such a range is expressed, also specifically contemplated and considered disclosed is the range from the one particular value and / or to the other particular value unless the context specifically indicates otherwise. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another, specifically contemplated embodiment that should be considered disclosed unless the context specifically indicates otherwise. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint unless the context specifically indicates otherwise. Finally, it should be understood that all of the individual values and sub-ranges of values contained within an explicitly disclosed range are also specifically contemplated and should be considered disclosed unless the context specifically indicates otherwise. The foregoing applies regardless of whether in particular cases some or all of these embodiments are explicitly disclosed.

[0045] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed method and compositions belong. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present method and compositions, the particularly useful methods, devices, and materials are as described. Publications cited herein and the material for which they are cited are hereby specifically incorporated by reference. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such disclosure by virtue of prior invention. No admission is made that any reference constitutes prior art. The discussion of references states what their authors assert, and applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of publications are referred to herein, such reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art.

[0046] Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps. In particular, in methods stated as comprising one or more steps or operations it is specifically contemplated that each step comprises what is listed (unless that step includes a limiting term such as “consisting of’), meaning that each step is not intended to exclude, for example, other additives, components, integers or steps that are not listed in the step.

[0047] The term “exosome” as used herein refers to a micro-vesicle of 50-100 nM diameter. The exosomes of the present invention are secreted from human adipose-derived stem cells.

[0048] As used herein, “hASC exosomes” refers to “exosomes isolated from human adipose- derived stem cells”.

[0049] The terms “compositions comprising hASC exosomes”, “composition”, and “pharmaceutical composition” are used interchangeably herein to refer to a composition comprising exosomes isolated from hASCs.

[0050] Inflammation in the brain, in particular activation of microglia and dendritic cells, has been increasingly associated with the pathogenesis of Parkinson’s disease (PD), as well as several other neurodegenerative disorders. The role of the adaptive immune system in concert with the innate immune system is another area of growing interest in the field of neurodegenerative diseases. Aside from the dramatic loss of dopaminergic neurons associated with PD, it has been shown that the substantia nigra (SN) is also the site of a robust glial reaction in PD patients and in humans with MPTP poisoning (Langston et al., 1999) and in response to oc- synuclein in both humans and animal models (Austin et al., 2006a; Reynolds et al., 2007b; Su et al., 2007b )(Su et al., 2008; Su et al., 2009) (Reynolds et al., 2009a; Reynolds et al., 2010).Increased numbers of microglia and the presence of pro-inflammatory microglia have been noted by many authors (McGeer and McGeer, 1997; Banati et al., 1998; Mirza et al., 2000), and they are present in both early and late stages of the disease. Activated microglia appear to have a Janus face in that there is upregulation of both neuroprotective and neurotoxic factors.Intracerebral implantation of microglia in rat models of PD has been shown to improve rotational behavior and increase tyrosine hydroxylase (TH) immunoreactivity, in agreement with the beneficial effect of activated microglia (Wang et al., 1991). On the other hand, the activation of microglia can lead to neuronal death. It has been proposed that the increases in microglia may be one of the early events that lead to the neurodegeneration. Activated microglia produce a wide array of cytotoxic factors, including reactive oxygen species (ROS) and pro-inflammatory cytokines and nitric oxide. It is postulated that high dose manganese toxicity, which resembles PD in many respects, is due to an activation of microglia which leads to production of nitric oxide and thus oxidative damage to neurons (Chang and Liu, 1999).

[0051] Microglia can transition through multiple activation states initially termed Ml, or classical pro-inflammatory, and M2, or alternative, activation (Mantovani et al., 2004; Morgan et al., 2005), including M2a, M2b and M2c subdivisions (Wilcock, 2012). Recently, a meeting summary (Heneka et al., 2015) concluded the number of microglial phenotypes vastly exceed those described in this nomenclature. Microglia are clearly pleiotropic and respond differently depending on the signals received. There is accumulating evidence that one change with age is the sensitivity of microglia to specific signals. Age-associated changes in microglial responsiveness may contribute to the development of synuclein pathology. Microglia arenormally in a surveying phenotype that is actively sensing the environment. When they encounter danger signals, such as extracellular oc-synuclein, they actively change into a pro- inflammatory phenotype with aspects of what has been termed Ml activation. Described herein is that one consequence of aging that predisposes the brain to neurodegen erative disease is that microglia are primarily in the pro-inflammatory state and show resistance to moving into the anti-inflammatory state.

[0052] It has been demonstrated that in the aged brain, microglia do not respond to the environment in the same manner as young microglia and there are high levels of IL-10 and TNFoc and low levels of IL-10 even under basal conditions (Gemma et al., 2002; Monje et aL, 2003; Gemma et al., 2005; Michaud et al., 2013; Flowers et al., 2017). A recent paper used either an Ml-based cocktail (IL 10 + IL-12) or an M2 cocktail (IL-4 + IL-13) to induce activation of microglia in the brains of young and old mice (Lee, Ruiz et al. 2013) and demonstrated that there was increased response to the Ml cocktail in the aged brain and reduced ability to respond to M2 stimuli. This phenomenon has been reproduced with isolated microglia and has been termed priming (Norden et al., 2014). In order to understand the molecular underpinnings of the changes in microglial function with age a number of investigations have begun to unravel changes in gene and protein expression in isolated microglia. A recent study using RNAseq compared isolated microglia to whole brain extracts and identified the microglial sensome (Hickman et al., 2013). These authors then examined the microglial sensome in aged microglia and a large number of the down -regulated sensome genes were related to sensing endogenous ligands whereas host defense genes were up-regulated. These authors also compared genes related to priming between young and aged and found down-regulation of classical activation genes and increases in alternate activation genes suggesting a shift towards alternate activation, in seeming contrast to findings discussed above where responses of microglia to these Ml and M2 stimulators suggested hyperactive classical activation and blunted alternative activation. It is also not clear how this relates to the changes in the sensome that were revealed, as this clearly shows that microglia sense the environment differently with age. Another recent study using gene microarrays of isolated microglia demonstrated up-regulation of a number of pathways including NFKB related genes and identified Sirtl epigenetic regulation of IL-10 as important in aged microglia (Cho et al., 2015).

[0053] Given these observations, the pleiotropic glial response, associated with dopaminergic neuron loss in SN may be related to the balance between pro-inflammatory and antiinflammatory phenotype. An increase in IFN-y is observed in PD (Liu, 2006), and in mice lacking INF-y, there is a protection from damage resulting from MPTP (Mount et al., 2007). Microglia are the immuno-competent cells of the brain. In the early phase of the injury they are promptly activated along the lines of anti-inflammatory / altemative pathways, and they express numerous molecules with important immune function and trophic action that can lead to neuroprotection (Batchelor et al., 1999). Later, their prolonged activation increases the expression of a variety of neurotoxic factors characteristic of a pro-inflammatory state and at this stage they may contribute to the degeneration of the dopaminergic neurons. The injury is more severe after blockade of the early anti-inflammatory response using antisense to TNFa on day 1 - 5 following a 6-OHDA-induced lesion of the striatum (Gemma et al., 2007) in agreement with the early anti-inflammatory / alternative activation state being neuroprotective. Blocking the late phase chronic pro-infl ammatory / classi cal activation resulted in a smaller lesion in agreement with the chronic pro-inflammatory phase being detrimental and a cause of ongoing DA cell death following the 6-OHDA injury (Gemma et al., 2007).

[0054] The neuroprotective capacity of mesenchymal stem cells (MSC’s) derived from adipose tissue has been of interest in regenerative medicine. Human adipose-derived stem cells (hASC’s) manifest a secretome that is capable of modulating the environment of the host. Among these secreted molecules, small membrane-bound vesicles known as exosomes have become of particular interest due to their cargo including cellular proteins, mRNA and miRNAs, and their ability to evade immune rejection by the host and modify immune responses (Gupta and Pulliam, 2014). Compelling evidence suggests that exosomes play an important role in cell- to-cell communication and have demonstrated improved functional recovery after stroke and TBI (Xin et al., 2013; Ge et al., 2015; Zhang et al., 2015). These MSC derived extracellular vesicles are also thought to modulate immune function as part of their mechanism of action following both TBI and epilepsy (Kim et al., 2016; Long et al., 2017). Of the cargo secreted in exosomes, IncRNA MALAT1 controls important biological processes such as cellular proliferation and differentiation and is thought to have a role in regeneration after injury (Tajiri et al., 2014; El Bassit et al., 2017; Zhang et al., 2017). MALAT1 is also known to modulate immune cellexpression of TNFoc and IL-6 following LPS stimulation (Zhao et al., 2016). MALAT1 plays an important role in the action of the secretome of hASC’s to repair damage following TBI (Tajiri et al., 2014). MALAT1 is part of the hASC exosomes cargo important for protecting neurons from oxidatively induced injury (Patel et al., 2016). Described herein is the use of exosomes as a cell- free regenerative approach in the rAAV9 oc-synuclein model of Parkinson’s disease.

[0055] Exosomes due to their small size are excellent therapeutic “packages” that can readily be taken up by cells and cross the blood brain barrier. Delivery can easily be achieved with several routes, including intranasal (Long et al., 2017). Exosomes when delivered intranasally easily penetrate the brain and are found in neurons and microglia and have an anti-inflammatory action (see Fig 6) (Long et al., 2017). As described herein, this cell free therapy will be examined in models of PD as potent modulators of inflammation as well as promoters of neural regeneration.

[0056] There is ample evidence that Parkinson’s disease is a major debilitating disease that affects many veterans. This disorder and related Parkinsonian signs are associated with a significant risk of morbidity and mortality in elderly veterans. Furthermore, Gulf War Illness (GWI) has been associated with a similar phenotype and loss of dopamine cells in the substantia nigra. This set of neurodegenerative diseases impacts veteran’s ability to locomote as one of the main symptoms is bradykinesia. PD also decreases a veteran’s ability to carry out normal tasks of daily living as the disease progresses and becomes more debilitating. Understanding the basis of this neurodegenerative process can lead to the design and development of appropriate pharmacological therapies for intervention such as drugs that interfere with the balance of inflammation and neuroprotection. Exosomes, delivered by the intranasal route, as described herein, can be readily translated into the clinic as this is a non-invasive mode of delivery.Compositions

[0057] Disclosed herein are compositions comprising exosomes isolated from human adipose-derived stem cells (hASC exosomes). The hASC exosomes can be obtained or isolated from hASCs by any suitable method known in the art. The compositions comprising hASC exosomes disclosed herein can further comprise insulin.

[0058] The compositions comprising hASC exosomes can further comprise a pharmaceutically acceptable carrier or excipient. Pharmaceutically acceptable carriers typically include at least one of diluents, lubricants, binders, disintegrants, colorants, flavors, sweeteners, antioxidants, preservatives, glidants, solvents, suspending agents, wetting agents, surfactants, pH adjusting additives, combinations thereof, and others. The route by which the disclosed compounds are administered and the form of the composition will dictate the type of carrier to be used.

[0059] Such pharmaceutical carriers can be sterile liquids, such as water and oils. For example, the carrier can be a petroleum oil such as mineral oil; vegetable oil such as peanut oil, soybean oil, or sesame oil; animal oil; or oil of synthetic origin. Suitable carriers also include ethanol, dimethyl sulfoxide, glycerol, silica, alumina, starch, sorbitol, inosital, xylitol, D-xylose, mannitol, powdered cellulose, microcrystalline cellulose, talc, colloidal silicon dioxide, calcium carbonate, magnesium carbonate, calcium phosphate, calcium aluminium silicate, aluminium hydroxide, sodium starch phosphate, lecithin, and equivalent carriers and diluents. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like. The compositions comprising hASC exosomes can contain minor amounts of wetting or emulsifying agents. The compositions comprising hASC exosomes can contain pH buffering agents.

[0060] The compositions comprising hASC exosomes can be in a variety of forms. For example, the compositions comprising hASC exosomes may be in solid form, semi-solid form, or a liquid dosage forms. The compositions comprising hASC exosomes can be in the form of tablets, pills, powders, liquid solutions or suspensions, suppositories, and injectable or infusible solutions. The preferred form depends on the intended mode of administration and therapeutic application. For example, the compositions comprising hASC exosomes can be in liquid form for intravenous administration. As another example, the compositions comprising hASC exosomes can in a form suitable for intranasal administration. For example, the compositions comprising hASC exosomes can be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol, or oil for intranasal administration.Methods

[0061] Disclosed herein are methods of treating Parkinson’s disease in a subject or a subject with Parkinson’s disease. The methods of treating Parkinson’s disease in a subject or a subject with Parkinson’s disease can comprise administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASC exosomes). In some aspects, the hASC exosomes can comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA. In some aspects, the method can result in increased proliferation and survival of neurons in the subject. In some aspects, the method can result in an increase in motor function of the subject. In some aspects, the method can result in a decrease in striatal lesion volume in the subject. In some aspects, the method can result in an increase in neuronal functioning in the subject. In some aspects, the method can result in an increase in neuronal cell proliferation and migration in the subject. In some aspects, the composition can be administered intranasally or intravenously. In some aspects, the subject can be a human. In some aspects, the method can further comprise administering insulin to the subject. In some aspects, the insulin can be administered to the subject separately from the composition comprising hASC exosomes. In some aspects, the composition can further comprise insulin.

[0062] Also disclosed herein are methods of preventing Parkinson’s disease in a subject. In some aspects, the subject can be at risk for developing Parkinson’s disease. In some aspects, the method can comprise administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASC exosomes). Disclosed are methods of preventing Parkinson’s disease in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells. In some aspects, the hASC exosomes can comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA. In some aspects, the method can result in increased proliferation and survival of neurons in the subject. In some aspects, the method can result in an increase in motor function of the subject. In some aspects, the method can result in a decrease in striatal lesion volume in the subject. In some aspects, the method can result in an increase in neuronal functioning in the subject. In some aspects, the method can result in an increase in neuronal cell proliferation and migration in the subject. In some aspects, the composition can be administered intranasally or intravenously. In some aspects, the subject can be a human. In someaspects, the method can further comprise administering insulin to the subject. In some aspects, the insulin can be administered to the subject separately from the composition comprising hASC exosomes. In some aspects, the composition can further comprise insulin.

[0063] Disclosed herein are methods of protecting neurons from cell death in a subject with or at risk for developing Parkinson’s disease. In some aspects, the methods can comprise administering to the subject a composition comprising exosomes isolated from human adipose- derived stem cells (hASC exosomes). Disclosed are methods of protecting neurons from cell death in a subject with or at risk for developing Parkinson’s disease, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose- derived stem cells. In some aspects, the hASC exosomes can comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA. In some aspects, the method can result in increased proliferation and survival of neurons in the subject. In some aspects, the method can result in an increase in motor function of the subject. In some aspects, the method can result in a decrease in striatal lesion volume in the subject. In some aspects, the method can result in an increase in neuronal functioning in the subject. In some aspects, the method can result in an increase in neuronal cell proliferation and migration in the subject. In some aspects, the composition can be administered intranasally or intravenously. In some aspects, the subject can be a human. In some aspects, the method can further comprise administering insulin to the subject. In some aspects, the insulin can be administered to the subject separately from the composition comprising hASC exosomes. In some aspects, the composition can further comprise insulin. In some aspects, the subject has been diagnosed with Parkinson’s disease or is a risk for developing Parkinson’s disease.

[0064] Disclosed herein are methods of reducing or preventing dopaminergic cell loss in the substantia nigra pars compacta in a subject. In some aspects, the methods can comprise administering to the subject a composition comprising exosomes isolated from human adipose- derived stem cells (hASC exosomes). Disclosed are methods of reducing or preventing dopaminergic cell loss in the substantia nigra pars compacta in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose- derived stem cells. In some aspects, the hASC exosomes can comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA. In some aspects, the method canresult in increased proliferation and survival of neurons in the subject. In some aspects, the method can result in an increase in motor function of the subject. In some aspects, the method can result in a decrease in striatal lesion volume in the subject. In some aspects, the method can result in an increase in neuronal functioning in the subject. In some aspects, the method can result in an increase in neuronal cell proliferation and migration in the subject. In some aspects, the composition can be administered intranasally or intravenously. In some aspects, the subject can be a human. In some aspects, the method can further comprise administering insulin to the subject. In some aspects, the insulin can be administered to the subject separately from the composition comprising hASC exosomes. In some aspects, the composition can further comprise insulin. In some aspects, the subject has been diagnosed with Parkinson’s disease or is a risk for developing Parkinson’s disease.

[0065] Disclosed herein are methods of reducing or preventing loss of tyrosine hydroxylase in a subject. In some aspects, the methods can comprise administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASC exosomes). Disclosed herein are methods of reducing or preventing loss of tyrosine hydroxylase in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells. In some aspects, the hASC exosomes can comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA. In some aspects, the method can result in increased proliferation and survival of neurons in the subject. In some aspects, the method can result in an increase in motor function of the subject. In some aspects, the method can result in a decrease in striatal lesion volume in the subject. In some aspects, the method can result in an increase in neuronal functioning in the subject. In some aspects, the method can result in an increase in neuronal cell proliferation and migration in the subject. In some aspects, the composition can be administered intranasally or intravenously. In some aspects, the subject can be a human. In some aspects, the method can further comprise administering insulin to the subject. In some aspects, the insulin can be administered to the subject separately from the composition comprising hASC exosomes. In some aspects, the composition can further comprise insulin. In some aspects, the subject has been diagnosed with Parkinson’s disease or is a risk for developing Parkinson’s disease.

[0066] Disclosed herein are methods of reducing MHCII expression in a subject. In some aspects, the methods can comprise administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASC exosomes). Disclosed herein are methods of reducing MHCII expression in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells. In some aspects, the hASC exosomes can comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA. In some aspects, the method can result in increased proliferation and survival of neurons in the subject. In some aspects, the method can result in an increase in motor function of the subject. In some aspects, the method can result in a decrease in striatal lesion volume in the subject. In some aspects, the method can result in an increase in neuronal functioning in the subject. In some aspects, the method can result in an increase in neuronal cell proliferation and migration in the subject. In some aspects, the composition can be administered intranasally or intravenously. In some aspects, the subject can be a human. In some aspects, the method can further comprise administering insulin to the subject. In some aspects, the insulin can be administered to the subject separately from the composition comprising hASC exosomes. In some aspects, the composition can further comprise insulin. In some aspects, the subject has been diagnosed with Parkinson’s disease or is a risk for developing Parkinson’s disease.

[0067] Disclosed herein are methods of increasing pro-inflammatory signaling in the IL10 pathway and the NFKB pathway in a subject. In some aspects, the methods can comprise administering to the subject a composition comprising exosomes isolated from human adipose- derived stem cells (hASC exosomes). Disclosed herein are methods of increasing pro- inflammatory signaling in the IL 10 pathway and the NFKB pathway in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells. In some aspects, the hASC exosomes can comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA. In some aspects, the method can result in increased proliferation and survival of neurons in the subject. In some aspects, the method can result in an increase in motor function of the subject. In some aspects, the method can result in a decrease in striatal lesion volume in the subject. In some aspects, the method can result in an increase in neuronal functioning in the subject. In some aspects, themethod can result in an increase in neuronal cell proliferation and migration in the subject. In some aspects, the composition can be administered intranasally or intravenously. In some aspects, the subject can be a human. In some aspects, the method can further comprise administering insulin to the subject. In some aspects, the insulin can be administered to the subject separately from the composition comprising hASC exosomes. In some aspects, the composition can further comprise insulin. In some aspects, the subject has been diagnosed with Parkinson’s disease or is a risk for developing Parkinson’s disease.

[0068] Disclosed herein are methods of reducing the amount of TNFoc secreted in microglia in a subject. In some aspects, the methods can comprise administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASC exosomes). Disclosed herein are methods of reducing the amount of TNFoc secreted in microglia in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells. In some aspects, the hASC exosomes can comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA. In some aspects, the method can result in increased proliferation and survival of neurons in the subject. In some aspects, the method can result in an increase in motor function of the subject. In some aspects, the method can result in a decrease in striatal lesion volume in the subject. In some aspects, the method can result in an increase in neuronal functioning in the subject. In some aspects, the method can result in an increase in neuronal cell proliferation and migration in the subject. In some aspects, the composition can be administered intranasally or intravenously. In some aspects, the subject can be a human. In some aspects, the method can further comprise administering insulin to the subject. In some aspects, the insulin can be administered to the subject separately from the composition comprising hASC exosomes. In some aspects, the composition can further comprise insulin. In some aspects, the subject has been diagnosed with Parkinson’s disease or is a risk for developing Parkinson’s disease.

[0069] Disclosed herein are methods of reducing microglial activation in the substantia nigra in a subject. In some aspects, the methods can comprise administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASC exosomes). Disclosed herein are methods of reducing microglial activation in the substantia nigra in a subject, the method comprising administering to the subject a composition comprisingexosomes isolated from human adipose-derived stem cells. In some aspects, the hASC exosomes can comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA. In some aspects, the method can result in increased proliferation and survival of neurons in the subject. In some aspects, the method can result in an increase in motor function of the subject. In some aspects, the method can result in a decrease in striatal lesion volume in the subject. In some aspects, the method can result in an increase in neuronal functioning in the subject. In some aspects, the method can result in an increase in neuronal cell proliferation and migration in the subject. In some aspects, the composition can be administered intranasally or intravenously. In some aspects, the subject can be a human. In some aspects, the method can further comprise administering insulin to the subject. In some aspects, the insulin can be administered to the subject separately from the composition comprising hASC exosomes. In some aspects, the composition can further comprise insulin. In some aspects, the subject has been diagnosed with Parkinson’s disease or is a risk for developing Parkinson’s disease.

[0070] In some aspects, the subject or patient can be undergoing other forms of treatment.

[0071] In some aspects, the subject can be diagnosed with Parkinson’s disease or parkinsonism or a movement disorder associated with a reduction of dopamine or a loss of dopaminergic cells.

[0072] The compositions comprising hASC exosomess may be administered to the subject by any suitable route. The compositions comprising hASC exosomes may be administered orally, parentally (including intravenous, subcutaneous, topical, transdermal, intradermal, transmucosal, intraperitoneal, intramuscular, intracapsular, intraorbital, intracardiac, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and epidural injection) by infusion, by electroporation, or co-administered as a component of any medical device or object to be inserted (temporarily or permanently) into a subject. In some aspects, the compositions comprising hASC exosomes can be administered intransally. In some aspects, the compositions comprising hASC exosomes can be administered intravenously.

[0073] The compositions comprising hASC exosomes can be administered independently to the subject. The compositions comprising hASC exosomes can be administered to the subject in combination with insulin. In some aspects, the composition administered to the subject cancomprise exosomes isolated from human adipose-derived stem cells and insulin. The compositions comprising hASC exosomes and insulin can be administered simultaneously to the subject. The compositions comprising hASC exosomes and insulin can be administered separately to the subject. For example, insulin can be administered to the subject at a different site from the compositions comprising hASC exosomes. As another example, insulin can be administered to the subject by a different route than the compositions comprising hASC exosomes. The compositions comprising hASC exosomes and the insulin can be administered sequentially to the subject. For example, insulin can be administered to the subject before the compositions comprising hASC exosomes. Insulin can be administered to the subject after the compositions comprising hASC exosomes. Sequential administration can involve treatment with insulin on the same day (within 24 hours) of treatment with the compositions comprising hASC exosomes. Sequential administration can also involve continued treatment with insulin on days that the compositions comprising hASC exosomes is not administered.

[0074] The compositions comprising hASC exosomes can be administered in combination with other therapies for the treatment of Parkinson’s disease or parkinsonism. Other therapies include but are not limited to, lesion surgery, deep brain stimulation, and neural grafting or tissue transplants. Other therapies can include medications to reduce other risks associated with Parkinson’s disease or parkinsonism. In some aspects, the compositions comprising hASC exosomes can be administered in combination with anti-anxiety medications, antidepressants, diuretics, muscle stimulants, and the like. Other therapies include but are not limited to exercise, physical therapy, speech therapy, and nutrition. Other therapies can include medications to reduce symptoms of the disease such as slow movements and stiff, rigid body parts, dopamine replacement therapies, such as dopamine agonists; anticholinergics; MAO-B inhibitors; and COMT-inhibitors. Examples of drugs that can be administered in combination with the compositions comprising hASC exosomes include but are not limited to levodopa and carbidopa (Duopa, Rytary, Sinement); pramipexole (Mirapex), rotigotine (Neurpro), ropinirole (Requip), amantadine (Gocovri, Osmolex ER, Symmetrel); benztropine (Cogentin) and trihexyphenidyl (Artane); safinamide (Xadago), selegiline (Eldepryl, Zelapar), and rasagiline; and entacapone (Comtan), opicapone (Ongentys), and tolcapone (Tasmar).

[0075] Administration of the compositions comprising hASC exosomes can be as a single dose, or multiple doses over a period of time. The compositions comprising hASC exosomes can be administered to the patient at any frequency necessary to achieve the desired therapeutic effect. For example, the compositions comprising hASC exosomes can be administered once to several times every month, every two weeks, every week, or every day. Administration of the compositions comprising hASC exosomes can be repeated until the desired therapeutic effect has been achieved. For example, the compositions comprising hASC exosomes can be administered once to several times over the course of 1 day, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.

[0076] The amount of the compositions comprising hASC exosomes to be administered can depend on a variety of factors, such as the route of administration and the seriousness of the condition, and should be decided according to the judgment of the practitioner and each patient's circumstances. The compositions comprising hASC exosomes can be administered in any amount suitable for the treatment of the disease (e.g., Parkinson’s disease) in a subject. An effective amount of the compositions comprising hASC exosomes can cause a partial improvement or a complete elimination of symptoms due to the disease (e.g., Parkinson’s disease). Symptoms of Parkinson’s disease include but are not limited to tremor (e.g., can occur at rest, in the hands, limbs, or can be postural); muscular (e.g., stiff muscles, difficulty standing, difficulty walking, difficulty with bodily movements, involuntary movements, muscle rigidity, problems with coordination, rhythmic muscle contractions, slow bodily movement, or slow shuffling gait); sleep (e.g., early awakening, nightmares, restless sleep, or sleep disturbances; whole body (e.g., fatigue, dizziness, poor balance, or restlessness); cognitive (e.g., amnesia, confusion in the evening hours, dementia, or difficulty thinking and understanding); speech (e.g., difficulty speaking, soft speech, or voice box spasms; mood (e.g., anxiety or apathy); nasal (e.g., distorted sense of smell or loss of smell); urinary (e.g., dribbling of urine or leaking of urine); facial (e.g., jaw stiffness or reduced facial expression); blank stare; constipation; depression; difficulty swallowing; drooling; falling; fear of falling; loss in contrast sensitivity; neck tightness; small handwriting; trembling; unintentional writhing; or weight loss. Treatmentcan include promoting regeneration of neurons. Treatment can include enhancing survival of neurons. Treatment can include decreasing lesion size.

[0077] Suitable dosage ranges of the compositions comprising hASC exosomes include from about 0.001 pg exosome / kg body weight to about 100 mg / kg, about 0.01 pg / kg to about 90 mg / kg, about 0.1 pg / kg to about 80 mg / kg, about 1 pg / kg about 70 mg / kg, about 10 g / kg to about 60 mg / kg, about 0.1 mg / kg to about 50 mg / kg, about 0.5 mg / kg to about 25 mg / kg, about 1 mg / kg to about 10 mg / kg, or about 2.5 mg / kg to about 5 mg / kg. For example, suitable dosage ranges of the compositions comprising hASC exosomes include about 0.001 pg / kg, about 0.01 pg / k, about 0.1 pg / k, about 1 pg / k, about 10 pg / kg, about 0.1 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 2.5 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 40 mg / kg, about 50 mg / kg, about 60 mg / kg, about 70 mg / kg, about 80 mg / kg, about 90 mg / kg, or about 100 mg / kg.

[0078] Suitable dosage ranges of insulin include from about 0.001 pg insulin / kg body weight to about 100 mg / kg, about 0.01 pg / kg to about 90 mg / kg, about 0.1 pg / kg to about 80 mg / kg, about 1 pg / kg about 70 mg / kg, about 10 g / kg to about 60 mg / kg, about 0.1 mg / kg to about 50 mg / kg, about 0.5 mg / kg to about 25 mg / kg, about 1 mg / kg to about 10 mg / kg, or about 2.5 mg / kg to about 5 mg / kg. For example, suitable dosage ranges of insulin include about 0.001 pg / kg, about 0.01 pg / k, about 0.1 g / k, about 1 pg / k, about 10 g / kg, about 0.1 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 2.5 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 40 mg / kg, about 50 mg / kg, about 60 mg / kg, about 70 mg / kg, about 80 mg / kg, about 90 mg / kg, or about 100 mg / kg.

[0079] In addition, in vitro assays can optionally be employed to help identify optimal dosage ranges. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.Kits

[0080] Disclosed herein are kits. In some aspects, the kits can be used to treat Parkinson’s disease in a subject. The kit can comprise at least a composition comprising hASC exosomes. Instructions included in kits can be affixed to packaging material or can be included as a packageinsert. While the instructions are typically written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this disclosure. Such media include, but are not limited to, electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. As used herein, the term “instructions” can include the address of an internet site that provides the instructions.EXAMPLESExample 1: Effects of exosomes isolated from hASC in models of Parkinson’s disease.

[0081] Adeno-associated virus as a means to alter gene expression and induce progressive neurodegeneration. rA AV9 was used as the adeno-associated virus vector because of its superior performance in neuronal specific expression profile and because it will continue to produce gene expression for at least 1 year. Studies using rAAV expression of mutated a-synuclein have shown that there is significant cell death (greater than 50%) that lasts for longer than 1 year and is associated with Lewy body like inclusions (Klein et al., 2002).

[0082] The AAV model can be used to produce a slowly developing lesion that resembles progression of PD. When human WT a-synuclein (rAAV9-Syn) is expressed in the SN of rats, this leads to a slowly progressive lesion where there is 20% cells loss at 4 weeks and 60% cell loss at 6 months (Pabon et al., 2012; Shahaduzzaman et al., 2015). Thus, this model was chosen to examine the effects of drug treatments on progression of neurodegeneration following overexpression of WT a-synuclein. This works well in rat studies; however, the model in mice has been more challenging, and some of the studies have used the neurotoxin MPTP in mice. This model is associated with a more acute lesion; however, it resembles some aspects of PD such as DA cell loss and induction of microglial activation (Morganti et al., 2012).

[0083] Using the rAAV9-Syn, it has been have shown that the soluble form of CX3CL1 shows the potent action of preventing DA cell loss (Nash et al., 2015). It has also been demonstrated that antibodies against either the N-terminal or the central region of a-synuclein could reduce the pathology associated with synuclein (Shahaduzzaman et al., 2015).

[0084] Aging reduces the efficacy of treatments in an MPTP model ofPD pathology. It has been demonstrated that astaxanthin (AXT) supplementation can reduce the neurotoxicity of MPTP in mice 3 months of age (Grimmig, 2017). However, it is important to note that many compounds that have been successful pre-clinically have largely failed in clinical trials and a need for agents that can halt the neurodegenerative process remains unmet (Olanow and Kordower, 2009). Given that aging is in fact the biggest predictor of developing PD, the field has started to focus on the value of aged experimental animal models, with the thought that the physiology in aged animals is a more relevant backdrop to the human condition, possibly lending to more predictive validity. Therefore, the efficacy of AXT supplementation against MPTP neurotoxicity in aged animals (Grimmig et al., 2018) was investigated. Astaxanthin is a carotenoid that is produced by photosynthetic microorganisms. This compound has recently gained interest for its variety of health promoting effects (Guerin et al., 2003; Kidd, 2011; Yamashita, 2013). For example, AXT has been suggested to modulate immune function including microglial activation (Choi et al., 2008; Kim et al., 2010; Otton et al., 2010; Djordjevic et al., 2012; Zhou et al., 2015), enhance mitochondrial function (Liu et al., 2009; Lee et al., 2011; Park et al., 2013) and is known to be an effective antioxidant (Chan et al., 2009; Wang et al., 2010; Li et al., 2013; Zhang et al., 2014). Thus, it was used to test in the model of PD as described herein.

[0085] FIG. 1 shows that AXT is neuroprotective in young, but not aged mice.

[0086] The same reduced effect of AXT to protect against MPTP induced loss of TH fibers was observed in the aged mice. Some protection of neurons counted using NeuN was observed, demonstrating that there was a shift in the dose-response to AXT or the timing of recovery with age, rather than a total loss of efficacy in the aged mice.

[0087] Aged mice show exaggerated microglial response to MPTP. To examine if this action was mediated by an interaction with microglia, IBA-1. a pan microglial marker, was used. It was observed that AXT reduced microglial activation in young, but not aged mice, as measured by total IBA-1 staining and further by counting using unbiased stereological methods the numbers of IBA-1 positive cells with enlarged soma indicative of a pro-inflammatory phenotype (FIG. 2). Aged mice show an exaggerated response to MPTP under control conditions, as reflected inalmost 10 times higher numbers of activated cells following MPTP compared to those measured in young mice (FIG. 2).

[0088] Thus, the results demonstrate that age is an important factor when considering the action of anti-inflammatory modulation of PD progression. The aged mice had an exaggerated inflammatory response to the MPTP treatment (note scale for FIGS. 2B and 2C are different) and did not respond to AXT to reduce the inflammatory response (FIG. 2).

[0089] Aged microglia show exaggerated response to pro-inflammatory and blunted response to anti-inflammatory treatments, proteomic changes were examined in several aspects of microglial phenotype with age, and it was demonstrated that one of the changes that underlies the increased pro-inflammatory phenotype and the blunted anti-inflammatory phenotype observed with age is a decline in Rictor expression (Flowers et al., 2017). The difference in this study is in function of aged microglia in response to cytokine signals. As shown in FIG. 3, there is an augmented response of aged microglia to TNFoc and a blunted response to IL-4.

[0090] Transcriptomics will be used to analyze the microglia in the substantia nigra with age and the response to a-syn. Further, it will be determined whether hASCexo treatment targets relevant regulatory pathways in aged microglia.

[0091] Exosomes derived from human adipose derived stem cells (“hASC exosomes”) are potent modulators of inflammation. hASC exosomes have a potent anti-inflammatory action when administered in a traumatic brain injury model. Furthermore, this effect is be dependent upon inclusion of the IncMALATl. RNAseq was performed at 7 days following the injury and an increase in several networks of gene expression relating to pro-inflammatory responses was observed. For example, ILip is a highly upregulated network, driven by gene expression of 19 detected transcripts (FIG. 4). In animals treated with hASC exosomes (C vs TE), this network was decreased with respect to injury. For example, MMP9 was upregulated 3.6-fold following injury, but when comparing injury to hASCexo treatment MMP9 was decreased 1.9-fold. As another example, UCP3 was upregulated 2-fold but was unchanged with respect to control after hASCexo. This anti-inflammatory action was dependent upon the presence of MALAT1 in the exosomes (FIG. 4C). When hASC were grown in the presence of MALAT1 anti-sense DNA, which reduced MALAT1 in the exosomes by over 70% (C vs TEdM), the anti-inflammatoryaction was no longer observed and expression of genes in the IL11 network returned to a level similar to that observed with TBI (Patel et al., 2018).

[0092] hASC exosomes protect neurons for injury. Exosomes enhance HT22 neuronal survival and proliferation in a MALATl dependent manner. hASC exosomes protected against H2O2 induced cell death and increased proliferation as measured with Ki67 (FIG. 5). A wound assay was also performed by examining the movement of cells into a cell free region of the plate which was generated by scratch to remove cells (FIG. 5) (El Bassit et al., 2017).

[0093] Cells treated with hASC exosomes significantly improved proliferation and migration and removal of MALAT1 reduced the benefits of the exosomes.

[0094] hASC exosomes delivered by the intranasal route enter the brain and are found in neurons and microglia. Exosomes, due to their small size, can be used as therapeutic “packages” that can readily be taken up by cells and cross the blood brain barrier. Delivery can be achieved with several routes, including intranasal. Exosomes when delivered intranasally easily penetrate the brain and are found in neurons and microglia following in an epilepsy model (Long et al., 2017). A similar distribution was observed following brain injury. Merged images of GFP labelled hASC exosomes with either IB Al, MAP2 or GFAP show that numerous exosomes are found co-localized with neurons and microglia; however, very few are observed on the surface or inside astrocytes.

[0095] hASC exo treatment at 14 days after a-synuclein reduces both loss of TH andMHCII expression. The effect of intranasal hASC exosomes was examined on important aspects of neurodegeneration following rAAV9-synuclein. Ten rats were injected with rAAV9-synuclein unilaterally into the right SN. Two weeks later, at a time when synuclein expression is beginning (Pabon et al., 2012), subsets of 5 rats were treated with intranasal hASC exosomes (30 pg) or saline. Two weeks later, rats were euthanized, and brains prepared for IHC. FIG. 6 shows that this treatment prevented the loss of TH and expression of MHCII in microglia. These measures were examined at an early point in the progression of the TH loss and microglial activation; the results demonstrate that this method will modify neuropathology at later times. Synuclein expression staining showed no differences between groups, demonstrating that the hASCexo didnot disrupt the amount of AAV-synuclein expression, but did reduce TH loss, likely via the interaction with microglia. These data show that the neurorestorative approach will have effects on microglial phenotype.Example 2: hASC exosomes as a cell free therapeutic modulates neuropathology and neurotoxicity in an rAAV-Syn model of PD and a 6-OHDA model of PD.

[0096] Aging is the primary risk factor for PD. Aging impacts microglial phenotype, reducing the efficacy of some therapeutics. It is tested whether hASC exosomes alter microglial function at a genomic level by delivery of IncRNA MALAT1, and other important factors, thus making them available for use in aged subjects. First, microglia will be isolated from young and aged rats, treated with and without intranasal hASC exosomes and transcriptomic profiling will be performed. Microglia genomic profiles will be characterized during progression of an AAV9-0C- synuclein model of PD in young and aged rats.

[0097] As shown herein aged microglia are hyper-responsive to MPTP, and that this change is not responsive to a therapeutic (astaxanthin) that is effective in young mice. It is further expected that they will be hyper-responsive to a-synuclein, and this underlies why some therapeutics that are effective in animal models fail to be translated to the clinic, as they are not tested in aged animals. FIG. 4 demonstrates that hASC exosomes modulate inflammation at the genomic level following brain injury. Thus, it is predicted that hASC exosomes will have potent effects to both decrease the exaggerated pro-inflammatory effect, but also augment antiinflammatory actions in microglia. Microglia undergo a complex phenotypic response to both age and synuclein. These changes with age are discussed herein. Microglia also respond to a- synuclein. For example, it has been demonstrated a complex response to nitrated a-synuclein including activation of NFKB, and also involving regulation of cell motility, metabolism, and chaperones (Reynolds et al., 2009b). A second proteomic study focused specifically on membrane-associated proteins involved in endocytosis, demonstrating an upregulation of clathrin and calnexin (Liu et al., 2007). Surprisingly, few studies have directly examined microglial phenotype following synuclein exposure in vivo with age as a co-factor. Therefore, an unbiased transcriptomics based analysis of microglial phenotype following induction of a-synuclein expression using Clariom D gene chips (ThermoFisher).

[0098] hASC exosomes will modify microglial phenotype in young and aged rats in a MALAT 1 dependent manner.

[0099] Method. Exosome preparation will be as follows. Briefly, conditioned media (CM) derived from hASC cells (exosome free serum is used in the media to grow the hASC cells so that FBS derived exosomes do not contaminate the preparation) is collected after 48h and centrifuged at 3000 g for 15 min to remove dead cells. Exosomes are isolated by size exclusion column (ExoSpin™, Cell Guidance Systems) into PBS. The exosome sizes and purity are confirmed by NanoSight.

[0100] Groups of 12 rats (both male and female) at 3 months or 18 months of age will be treated with either intranasal vehicle (8 pl per nostril), hASCexo (8 pl per nostril, 30pg total dose), or hASCexo -MALAT1 (8 pl per nostril, 30pg total dose) for a total of 72 rats. Female rats are included as there have been shown to be differences between microglia in males and females (Guneykaya et al., 2018), although some of these changes are observed regionally it remains important to examine both sexes. One week following exosome treatment, microglia will be isolated from the rat substantia nigra / midbrain. One group will also be examined at the time of exosome treatment. Substantia nigra / midbrain is isolated, and then following dissociation and debris removal using a 30% percoll spin, microglia are then purified using Miltyeni rat specific CD1 lb,c magnetic isolation beads (Flowers et al., 2017), and modified for the rat. It is expected that sufficient RNA extraction from individual bilateral midbrain sections for a single rat to yield the minimum of 50 ng RNA resulting in n = 6 male and 6 female samples to run on the Clariom D gene rat transcriptome microchips (ThermoFisher) to yield a broad spectrum of coding and non-coding RNA.

[0101] Gene expression data will be filtered for significance at a 2-fold cutoff and then entered into Ingenuity Pathway Analysis for bioinformatics. DAVID and other available platforms will also be used. Gene identifications will be submitted for functional analysis, global network mapping, and gene ontology analysis to identify potential functionally relevant pathways. These analyses are routinely performed and have consistently provided conceptual and mechanistic information from transcriptomics data for further targeted studies.

[0102] Statistics. Based upon past datasets, gene expression analysis will result in a CV of less than 30% across the spectrum of targets, an N=6 is sufficient to achieve statistical significance at >2-fold change. Thus, as there are potential differences between male and female N=6 per gender per condition is used. Statistical tests will include consideration of both variance as well as z-score cutoff (|z-score|>l) using the variance test parameters. Moreover, combining these tests for statistical filtering yields an acceptable FDR (10%). Within IPA analysis will further determine the significance of overlap of detected targets through a Fisher’s exact test (p<0.05) in addition to a z-score algorithm to predict the direction of upstream regulator change (significant activation or inhibition established at a z-score of >2 or <-2, respectively). The same statistical analyses will be performed to predict functional outcomes based on differential gene expression (e.g., immune cell activation, oxidative stress response, specific cell signaling pathways, etc.). Validation of the upstream regulator and functional outcome predictions will be examined by relevant RT-PCR, Western blot and activity assay approaches (Bell-Temin et al., 2013; Flowers et al., 2017; Patel et al., 2018) to determine the impact of the exosome treatment on microglial phenotype.

[0103] It is predicted that hASC exosomes will bring many of the age-related alterations in microglial phenotypic alterations back towards that of the young. The advantage of the exosome treatment strategy is that a package of microRNA and IncRNA is being used that will have effects on multiple molecular mechanisms. It is expected that the hASC exosomes will show targeted effects on inflammatory pathways and metabolic changes in mitochondrial function. It is further expected that the hASC exosomes with reduced MALAT1 will have a reduced action to modulate inflammatory molecular pathways.

[0104] HASC exosomes may modulate microglial response to a-synuclein in young and aged rats.

[0105] Method. Groups of 12 (male and female) rats at 3 months or 18 months of age will be injected bilaterally into the substantia nigra with either rAAV9-Syn or rAAV9-GFP at day 0. The titer is set to induce a 50% cell loss at three months in both young and age rats, thus even with bilateral lesion the rats will be able to ambulate and feed normally. It takes about 2 weeks after AAV9 for a-synuclein to begin expressing protein in significant amounts and 3 - 4 weeks beforecell death begins (Pabon et al., 2012). For this study, the time point after cell death has progressed and behavioral deficits become apparent at 7 weeks post synuclein treatment will be the focus. This is equivalent to a clinically relevant intervention time post-symptom onset. At 7 weeks post AAV-9 treatment, rats will be treated with either intranasal vehicle (8 pl per nostril), hASC exosomes (8 pl per nostril, 30 pg total dose), or hASC exosomes -MALAT1 (8 pl per nostril, 30 pg total dose). A group of rats treated with synuclein and not treated with exosomes will be taken at 7 weeks to assess microglial transcriptome at the time that exosomes treatment begins. 152 rats will be used. One week following exosome treatment, microglia will be isolated from the rat midbrain as described herein. For this experiment, synuclein treatment is bilateral and RNA will be isolated from both hemispheres to obtain sufficient RNA for the chips without pooling animals. Unilateral injections will also be used in another experiment as this allows for behavioral characterization of paw bias. Transcriptomic profiling will be performed as described herein.

[0106] A second model of PD in rats, using bilateral intrastriatal 6-OHDA model, will be used. In this model, DA cell loss progresses over 1 - 2 months, thus hASC exosomes or vehicle will be administered at 4 weeks instead of 7 weeks as there is already symptom onset at this time in that model. Microglia will be isolated one week later.

[0107] Primary outcomes will be a comparison of molecular phenotype in response to synuclein or 6-OHDA in the young vs aged rats, and how that changes in response to treatment with hASC exosomes when examined in comparison to the age-matched baselines. It is predicted that in response to synuclein or 6-OHDA, an increase in pro-inflammatory signaling including ILip and NFKB pathways will be observed, and disease associated microglia molecular patterns will also be assessed. It is predicted that these observations will be exaggerated in the aged rats following synuclein or 6-OHDA. Metabolic pathways such as mitochondrial function and mTOR signaling will also be examined. As aging significantly modifies microglial phenotype, the effects of hASC exosomes in young and aged microglia will be determined. It is predicted that as the exosomes are delivering non-coding RNA that is modulating cellular phenotype at the genomic level, that this would have an effect in the aged microglia. MALAT1 is predicted to be an important aspect of this action, and exosomes depleted of MALAT1 will not show the sameaction. The data shows that with intranasal hASC exosomes at two weeks post AAV-syn, a reduction in microglial activation and protection from TH loss is observed..

[0108] Exosomes will have a wide impact of therapeutic action and will likely impact microglia and neurons directly to improve resilience to oc-synuclein toxicity in young and aged rats. As shown herein, hASC exosomes enter neurons and microglia following intranasal delivery, thus exosomes could have a two-fold neuroprotective action. The neuroprotective action of hASC exosomes on isolated microglia and on SH-SY5Y cells transformed to dopaminergic cells and primary rat neurons in culture will be examined when exposed to increased oc-synuclein.

[0109] hASC exosomes will directly impact the functional response of microglia to oc- synuclein in culture as measured with assessment of cytokine release, phagocytosis and cell migration. As a validation of the transcriptomics experiments, three measures of functional outcomes in young and aged microglia will be measured.

[0110] Method. Primary microglia will be harvested from both aged and young rats and treated with hASC exosomes ex vivo. To further determine the role of MALAT1, MALAT1 depleted hASC exosomes will be used, and expression of MALAT1 will be directly increased in microglia.

[0111] Using this isolation protocol, microglia was successfully cultured and the response to pro-inflammatory and anti-inflammatory stimuli was assessed (see FIG. 3). 4,000,000 cells per rat forebrain will be isolated, thus microglia from 3 rats will be pooled to get sufficient cells to run the conditions listed herein for a single biological replicate for each treatment studied. Each experiment will be done with a minimum of five biological replicates of microglia pooled from different rats. TNFoc release, phagocytosis and cell proliferation / migration will be assessed. These conditions will also be examined using a human microglial cell line HMC3.

[0112] Primary microglia isolated from young and aged rats will be grown in DMEM / F12 with 10% FBS, 2 mM glutamax and 100 units / ml penicillin / streptomycin. They are allowed to grow for two days to allow them to adhere and begin to send out processes. WT oc-synuclein oligomers will be generated by incubating 100 pM synuclein at pH 7.5 in 1 pM heparin for 48hours. Particle size will be validated with the NanoSight. This will be done routinely to assure that the synuclein oligomers preparations are consistent and reproducible. For this experiment, both young and aged microglia will be grown in 96- or 24-well plates. Treatment conditions (at 48 hours in culture) for microglia will be no treatment, 5 pM WT a-synuclein, 5 pM WT a- synuclein treated 2 hours later 2 pg / ml hASC exosomes; 5 pM WT a-synuclein treated 2 hours later with 2 pg / ml hASC exosomes depleted of MALAT1, or increased MALAT1 expression via lipofectamine transfection on day 1 followed by 5 pM WT > -synuclein at 48 hours. As MALAT1 is known to interact with NFKB (Zhao et al., 2016), RNA IP experiments will be performed to determine whether this aspect of the mechanism is involved in microglia response to synuclein. Alterations in cytokine production, phagocytic activity and motility will also be examined. A set of cultures will also be examined at 2 hours after synuclein to compare to the function at the onset of exosome addition.

[0113] TNFa secretion. This experiment will be done in 96 well plates, the conditions run in triplicate wells, and a minimum of 6 biological replicates will be assessed. At the end of the 48 hours of treatment conditions listed herein, media will be collected and analyzed for TNFa by ELISA.

[0114] Phagocytosis will be assessed using pHrodo™ Green E. coli BioParticles™ (ThermoFisher Scientific). This assay will also be run in 24 well plates and has the advantage that the bioparticles do not emit fluorescence until they are contained in the lysosome, reducing the need for washing and any false positive fluorescence of particles on the cell membrane. Cytochalasin D (10 pM) is used as a negative control to inhibit

[0115] phagocytosis. Microglia are allowed grow for two days to allow them to adhere and begin to send out processes. They will be subjected to the conditions listed herein followed by replacement of the media with Live Cell Imaging Solution (ThermoFisher) plus the pHrodo™ Green A. coli BioParticles™. Microplates are analyzed with BioTek Cytation 3 Cell Imaging Multi-Mode Reader with temperature and CCh control for live cell assay and fluorescence will be measured at 1, 2 and 3 hours after administration of the bioparticles.

[0116] Cell Migration. Cell migration is measured using Ibidi culture insert wells in 24 well plates (Ibidi Cat No. 80241). The inserts have 2 compartments separated by 500 pm. Cells areplated into both compartments at the same density (25,000 cells), then the insert is removed after 48 hours. Cultures are examined at 24 and 48 hours after insert removal to determine the density of cells in the 500 pm zone.

[0117] RNA immunoprecipitation (RIP). These experiments will be done in microglial cell lines HAPI (rat) and HMC3 (human) for initial analysis as these techniques are sensitive and a large number of controls are needed. MALAT1 will be assessed from the exosomes in the various hASC exosome treatment groups (with or without synuclein). To begin to explore a possible mechanism of action of MALAT1, w RIP experiments will be performed. Zhao et al showed that p50 and p65 subunits of NFKB could interact with MALAT1 in THP1 macrophages. It will be determined if this interaction occurs in microglial cell lines. Briefly, the RIP assay kit is purchased from Sigma. Microglial cells treated with MALAT1 -containing exosomes are immunoprecipitated with p50 or p65 antibody. SNRNP70 and IgG antibodies serve as controls. RNA is purified and treated with DNAse to remove genomic DNA. SYBR Green Real-time qPCR is performed using primers for humanMALATl at the region where the putative binding site is predicted as well as with five different primers for regions spanning 500bp either side. The yield (% input) and specificity (fold enrichment) is calculated using Excel™ template for RIP from Sigma. Next, immunochemistry will be performed to determine whether MALAT1 sequesters NfkB in the nucleus or cytoplasm using FISH techniques and PSF for nuclear staining.

[0118] An increase in human MALAT1 associated with p50 and p65 in the hASC exosome treatment groups is expected. Human and rat MALAT1 will be distinguished and both will be measured in the HAPI cells, but not the HMC3 cells. The interaction with IL 113 and other cytokines and additional proteins of interest as identified will also be examined.

[0119] Statistical analysis. The conditions in an experiment are run in triplicate and then averaged together for a single biological replicate. Each experiment is run at least five times for 5 biological replicates. Statistical comparisons are done by using One or Two way ANOVA (Age and treatment) followed by post-hoc tests for query of specific comparisons between conditions.

[0120] Effects of the hASC exosomes on functional outcomes, especially in the aged microglia is expected. It is also predicted that the aged microglia will secrete higher levels of TNFa in response to a-synuclein. It is further predicted that hASC exosomes will reduce the amount of TNFa secreted in both young and aged microglia. It has been shown that aging alters phagocytosis and migration of microglia. For example in a proteomic study of aged microglia, cell migration and endocytosis are significantly changed with age (Flowers et al., 2017). Thus, in addition to the genomic evaluation examined, these functional outcomes will also be directly measured. It is expected that the aged microglia will have reduced phagocytosis,. The assay as designed uses E. coli bioparticles as an index of general function. Phagocytosis of a-synuclein will also be directly examined by conjugating it to the pHRodo backbone. The effect of exosomes on the function of the young microglia will be examined with the expectation that there will be an increase in phagocytosis and migration. A dose response curve can be performed to determine the effective dose of hASC exosomes. In some aspects, RNA pulldown assays can be carried out and MALAT1 can be purified to identify RNA binding proteins (Peirce magnetic RNA pulldown kit). With this procedure, MALAT1 is bound to the magnetic beads for isolation and then microglia protein lysates from the various conditions are used to capture RNA binding proteins. Mass spectrometry can also be used to identify additional proteins associated with MALATI.

[0121] hASC exosomes will directly protect neurons from WT a-synuclein.

[0122] As stated herein, there are significant interactions of the exosomes in both microglia and neurons. Thus, direct effects of hASC exosomes on neuronal protection can be observed. Alterations in the neuronal transcriptome with a-synuclein exposure will be examined and how this is affected by hASC treatment.

[0123] Method. Primary rat cortical neurons or SH-SY5Y cells terminally differentiated into dopaminergic neuron-like cells as described by Presgraves et al. (2004) will be used. Primary neurons are cultured in Neural Basal media with 10% B-27 and 0.1% glutamax. SH-SY5Y cells will be cultured in collagen-coated plates and allowed to grow for 3 days in normal growth medium (DMEM supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin) supplemented with lOpM retinoic acid (RA). Following this initial incubation, the medium isthen replaced with fresh growth medium containing 80 nM 12-O-tetradecanoyl-phorbol-13- acetate (TP A) for an additional 3 days. SH-SY5Y cells differentiated in this manner display enhanced sensitivity to MPP+ and increased expression levels of dopamine receptors in comparison to both undifferentiated cells and cells differentiated with RA alone. Additionally, cells differentiated with RA / TPA display higher levels of both dopamine transporter and tyrosine-hydroxylase, characteristic of dopamine neurons, than undifferentiated cells or cells differentiated with RA alone (Presgraves et al. 2004). TH expression will be used as a marker to confirm differentiation of the cells in culture. Primary rat cortical cells or SH-SY5Y DA cells will then be incubated for 2 hours with oligomeric WT oc-synuclein followed by addition of hASC exosomes (or MALAT1 depleted exosomes, or vehicle). After 20 hours, cells will be evaluated for markers of gene expression, viability and function. A set of cultures will be examined 2 hours after addition of synuclein.

[0124] Gene Expression. Gene expression will be examined. Affymatrix Clariom D gene microchips will be used to get a broad spectrum of coding and non-coding RNA (6.75 million probes). The data will be collected and sorted by pattern of changes. The analysis will focus on pathways related to neurodegeneration and neuronal repair. Filtered datasets can then be analyzed with various bioinformatics packages including IPA. Individual genes and non-coding transcripts or proteins will be validated using RT-PCR and the WES capillary protein detection system (Protein Simple).

[0125] C '.'ell viability. Neuronal viability will be assessed by LDH assay. Neuronal function will be evaluated by performing immunocytochemistry to assess TH-expression, and by examining mitochondrial dysfunction using an MTT assay for mitochondrial activity and mitoSOX to quantify production of mitochondrial ROS. WT a-synuclein oligomers will be generated as described herein. Protein levels of dopamine transporter will be analyzed by WES (Protein Simple). The data described herein show neuroprotection from a-SYN.

[0126] Cell Migration. Cell migration will also be examined using Ibidi culture insert wells in24 well plates (Ibidi Cat No. 80241). The inserts have 2 compartments separated by 500 pm. Cells are plated into both compartments at the same density (25,000 cells), the insert is removed after 48 hours. Cultures are examined at 24 and 48 hours after insert removal to determine thedensity of cells in the 500 m zone. For this experiment, both undifferentiated SH-SY5Y and differentiated SH-SY5Y cells, will be used as the differentiated cells may show low levels of migration but should extend processes into the cell free zone.

[0127] RIP. RIP will be performed as described herein. An increase in human MALAT1 associated with p50 and p65 in the hASC exosome treatment groups is expected. Experiments to distinguish between human and rat MALAT1 and measure both in the rat primary neurons will also be carried out.

[0128] It is expected that differentiated SH-SY5Y cells and primary rat cortical neurons treated with hASCexo will display enhanced survival and functionality when challenged with a- synuclein in comparison to cells treated with a-synuclein alone. Thus, an improvement in both survival and migration is expected. The gene expression data will be examined with both targeted and unbiased analysis. The effect of the hASC exosomes to modify redox stress pathways such as Nrf2 and Hiflot will also be assessed. Alterations in cell death / survival such as p53, caspase, WNT, MAPK, and neurotrophic factors is also expected. The Affymetrix Clariom D analysis will also reveal patterns in non-coding RNA. It is likely that MALAT1 will have significant actions on other ncRNA. The effect of MALAT1 alone can also be examined to further understand the role of MALAT1 in the exosomes versus other cargo. The results show that differentiated SH-SY5Y cells show protection by exosomes (FIG. 7).

[0129] It will be tested whether hASC exosomes, due to their potent anti-inflammatory actions and neuroprotective effects on neurons, will reduce PD symptomatology and pathology in both young and aged rats. It has been demonstrated that disruption of microglial pro- inflammatory signaling at points early on during synuclein aggregation can abrogate dopaminergic cell death; however, the question remains if this will also be an effective strategy after significant pathology and neurodegeneration has taken place. To examine this question, interventions with hASC exosomes at 7 post weeks AAV-9 synuclein a time when behavioral deficits are clearly manifesting and behavior and DA cell neuropathology will be followed and assessed. In a second cohort of animals, it will be tested whether later treatment (12 weeks) will be effective.

[0130] hASCexo intervention at the onset of pathology will prevent the development of motoric symptoms and neurodegeneration following AAV9-Syn in both young and aged rats. The rescue will be reduced in hASC exosomes depleted of MALAT1.

[0131] Method. Groups of 16 rats will be used. This number is needed so that there are sufficient rats for behavioral studies, subsequent subgroups of rats (8) will be studied in the endpoints described herein. The group size of 16 allows for sufficiently powered endpoints for the measures and was determined using power analysis of similar experimental design and allows for a = 0.05 and 13 = .8. The 8 rats per subgroup per outcome (e.g., immunohistochemistry) enables us to detect differences in the order of d = .67. Groups of 16 rats (8 male and 8 female, as gender will be examined separately) of 3 and 18 months of age will be treated unilaterally with rAAV9-Syn or rAAV9-GFP into the SN (2pl of IxlO13vg / ml) using CED delivery techniques to produce a 50% loss of DA neurons at 3 months post oc-synuclein treatment.

[0132] It takes about 2 weeks after AAV9 for a-synuclein to begin expressing protein in significant amounts and 3 - 4 weeks before cell death begins (Pabon et al., 2012). Thus, the hASC exosome treatments (30pg intranasal) will be timed to examine microglial phenotype after symptom onset. A second time of intervention will also be studied that coincides with a later phase at 12 weeks post induction of synuclein if further cell death has occurred. The rats will be tested on a cylinder test prior to any lesions or treatments and then again at 1, 2 and 3 months post a-synuclein (see (Nash et al., 2015; Shahaduzzaman et al., 2015)). In previous experiments, behavioral deficits are observed after 4 weeks and increase over time in this paradigm (. After the last behavioral test at 3 months, rats will be euthanized and split by behavioral test score into 2 groups with equivalent paw bias scores. One subgroup of rats (7) will be perfused with saline followed by 4% paraformaldehyde for immunohistochemical analysis for tyrosine hydroxylase (TH) to quantify numbers of dopamine expressing cells using unbiased stereological counting techniques. NeuN will also be quantified for total neuron numbers as it is well established that DA neurons lose TH expression but may not be dead. Microglia will also be quantified using MHCII (OX6) and a pan microglial marker CD1 lb. Synuclein oligomers will also be stained with Syn211 (ABCAM ab80627), F8H7 or syn33 (Rakez Kayed). Spreading of synuclein to the locus coeruleus and into the striatum as well as other brain regions will be assessed. Theassessments will take place at the end of 3 months. An additional group of rats will be assessed for loss of TH at the time of exosome treatment so that it can be determined if progression was stopped or recovery is promoted. The second subset of rats will be euthanized, and tissues collected for RNA and protein analysis. SN, striatum, cortex, hippocampus and cerebellum will be dissected. Tissue will be collected flash frozen and homogenized with Qiazole in order to obtain both RNA and protein. For protein, MSD V Plex will be used to measure IFN-y, IL-10, IL-13, IL-ip, IL-4, IL-5, IL-6, KC / GRO, TNF-a. For RNA, TaqMan inflammation panel will be used which will allow a broad range of inflammation related genes to be examined, including subpopulations of genes (e.g. Ml and M2 like groupings, chemokines and cytokines, disease associated microglial genes), as well as more open ended examination of the many facets of inflammation related genes. The protein and RNA measures include both pro-inflammatory and anti-inflammatory markers.

[0133] The effect of the hASC exosomes to rescue motoric behaviors in a second model, the instrastriatal 6-OHDA model, will also be tested. For this experiment, 6-OHDA (or vehicle) will be unilaterally delivered intrastriatally. Groups will be as described herein including male and female, young and aged with or without hASC exosomes (+ / -MALAT1) delivered intranasally. A subset of rats will be examined following 6-OHDA or vehicle at 4 weeks. In this model, symptoms develop after 2 or 3 weeks, thus the exosomes will be delivered at 4 weeks and then the rats will be followed with a second behavioral test at 8 weeks followed by euthanasia one week later. Many of the measures will be the same as for a-synuclein model including counting of TH positive cells in the SNpc. For this model, the volume of the TH-negative zone in the striatum will be quantified using the cavaleiri stereological probe (Pabon et al., 2011).

[0134] Statistical analysis. Statistical comparisons between groups are done by using One or Two way ANOVA (age and treatment) followed by post-hoc tests for query of specific comparisons between conditions.

[0135] hASC exosome intervention after additional cell death at 12 weeks will also reduce motoric symptoms and neurodegeneration following AAV9-Syn in both young and aged rats. The rescue will be reduced in hASC exosomes depleted of MALAT1. This approach would be indicative of a late stage therapeutic approach to the treatment of PD.

[0136] Groups of 16 male and female rats of 3 and 18 months of age will be treated unilaterally with rAAV9-Syn or rAAV9-GFP as described herein including the same treatment groups and conditions. In this experiment, interventions (30 pg intransal exosomes) will be carried out at 12 weeks post induction of synuclein and followed for an additional month with one extra behavioral test. This would be equivalent to a later diagnosis of PD. Immunohistochemical analysis of TH, NeuN and inflammatory markers as well as PCR arrays for the markers described herein will also be carried out.

[0137] A neuroprotective effect is expected after treatment with hASC exosomes at both 7 and 12 week in both young and aged rats. The data described herein supports this expectation. An assessment of a group of rats treated with a-SYN and quantified for TH immunostaining at the time of treatment will be performed which will allow the determination of whether the treatment is stopping progression of TH loss versus regeneration. It is also predicted that a significant protection will observed with the late intervention in both the young and aged rats. It is expected that the MALAT1 depleted exosomes will have reduced efficacy and not demonstrate a neuroprotective effect. The use of hASC exosomes in a second model of PD using intrastriatal 6-OHDA will also be assessed. This will help determine if any positive actions are related to synuclein specific toxicity or general neuroprotection and / or neurorestoration. The cell culture experiments show that it is a broad neuroprotective action that should cross between multiple models ofPD. For the biochemical analysis of cytokines and chemokines and other markers, non-motor areas hippocampus and cortex will be included.

[0138] In sum, hASC exosomes and their therapeutic impact on multiple cell types, neurons and microglia, which can improve resilience to a-synuclein toxicity and thus reduce neurodegenerati on .

[0139] Example 3: Therapeutic utility of adipose stem cell derived exosomes on a-synuclein induced neurodegeneration in rats.

[0140] Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease.Treatment options are limited but include medications, surgery, and lifestyle changes. Described herein are the use of exosomes derived from human adipose stem cells to treat PD.

[0141] Methods. To model PD, recombinant adeno-associated virus (AAV) which expresses a-synuclein (Syn) was injected into the substantia nigra (SN) of male rats. The rats were tested for paw bias at baseline to ensure there was not a paw preference difference between groups prior to initiation of the study. Rats received 2 pL of either rAAV9-Syn or the control vector rAAV9 mKate (0.5 xlO13vector genomes / mL). Three weeks after injection rats were split into different groups which received intranasal administration of either: 1) 100 pg hASC exosomes; 2) 60 pg hASC exosomes; or 3) PBS (control). mKate injected rats received intranasal PBS administration. At 4 and 8 weeks after viral administration the rats were tested in the cylinder task for their paw bias. Once complete the rats were euthanized and used immunohistochemistry to determine the extent of cell loss in the SNpc. FIG. 9 shows the timeline of the experimental design.

[0142] Results. Injection of hASC exosomes prevented the loss of dopamine in the SN pars compacta demonstrating a slowing of the progression of PD. hASC exosomes did not play a role in reducing paw bias within the two time points. A decrease in microglia activation was observed in groups that received a dose of exosomes. For example, FIG. 9 depicts a bar graph that shows paw preference at three different time points; baseline (before surgery), 1 month post-surgery, and 2 months post-surgery. No significant difference was observed between the groups 1- and 2- months post-surgery. FIG. 10 shows the percent area of positive cells in SNpc. Significant difference between Syn+ExolOO and Syn-PBS. Significant difference between mKate and Syn+PBS mean ±SEM. One Way ANOVA followed by post-hocs. *p<0.05; ** p<0.01. FIG. 11 shows representative photomicrographs of tyrosine hydroxylase (TH) staining (marker for dopamine neurons) in the SNpc after different treatments; demonstrating that the injection of hASC exosomes prevented the loss of dopamine in the SNpc. FIG. 12 shows the area ratio of microglia expressing MHCII (OX6) in the SN. A significant increase in MHCII+ cells following synuclein treatment was observed

[0143] In sum, hASC exosomes preserved dopaminergic neurons and play a role in reducing microglial activation in the substantia nigra in a rodent model of PD.Example 4: The molecular mechanisms of adipose stem cell derived exosomes for prevention of neurodegeneration in a-synuclein model of Parkinson’s disease.

[0144] Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disease.Treatment options are limited but include medications, surgery, and lifestyle changes. Described herein are the use of hASC exosomes derived from human adipose stem cells to treat PD.

[0145] Methods. To model PD, recombinant adeno-associated virus (AAV) which expresses a-synuclein (Syn) was injected into the substantia nigra (SN) of male rats. The rats were tested for paw bias at baseline to ensure there was not a paw preference difference between groups prior to initiation of the study. Rats received 2 pL of either rAAV9-Syn or the control vector rAAV9 mKate (0.5 xl013 vector genomes / mL). Three weeks after injection rats were split into different groups which received intranasal administration of either 100 pg hASC exosomes or PBS. mKate injected rats received intranasal PBS administration. At 4 and 8 weeks after viral administration, the rats were tested in the cylinder task for their paw bias. Once complete the rats were euthanized and used immunohistochemistry to observe cell loss and single cell RNA sequencing (scRNA seq) to observe changes in microglia and T cells.

[0146] Results. Injection of hASC exosomes prevented the loss of dopamine in the SN pars compacta, slowing the progression of PD. It was observed that Syn+PBS animals had increased inflammatory responses when compared to exosome treated animals. FIG. 14 shows that exosomes rescued dopaminergic neurons in SNpc. FIG. 15 shows UMAP of five distinct clusters separated by condition. Created using Seurat package.

[0147] Together, markers in cluster A and B of Syn+PBS animals (see, FIG. 16) are involved in increased immune response, microglia cytotoxicity, and T cell activation. These results support the IHC observations showing significant cell loss in the SNpc. Cluster B (FIG. 16B) shows that exosomes are involved in pathways that help maintain microglia homeostasis and aid in phagocytosis of damaged cells.

Claims

CLAIMSWHAT IS CLAIMED IS:

1. A method of treating Parkinson’s disease in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells.

2. A method of preventing Parkinson’s disease in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells.

3. A method of protecting neurons from cell death in a subject with or at risk for developing Parkinson’s disease, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells.

4. A method of reducing or preventing dopaminergic cell loss in the substantia nigra pars compacta in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells.

5. A method of reducing or preventing loss of tyrosine hydroxylase in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells.

6. A method of reducing MHCII expression in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells.

7. A method of increasing pro-inflammatory signaling in the ILip pathway and the NFKB pathway in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells.

8. A method of reducing the amount of TNFa secreted in microglia in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells.

9. A method of reducing microglial activation in the substantia nigra in a subject, the method comprising administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells.

10. The method of any of the preceding claims, wherein the isolated exosomes comprise metastasis associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA.

11. The method of any of the preceding claims, wherein the method results in increased proliferation and survival of neurons in the subject.

12. The method of any of the preceding claims, wherein the method results in an increase in motor function of the subject.

13. The method of any of the preceding claims, wherein the method results in a decrease in striatal lesion volume in the subject.

14. The method of any of the preceding claims, wherein the method results in an increase in neuronal functioning in the subject.

15. The method of any of the preceding claims, wherein the method results in an increase in neuronal cell proliferation and migration in the subject.

16. The method of any of the preceding claims, wherein the composition is administered intranasally or intravenously.

17. The method of any of the preceding claims, wherein the subject is a human.

18. The method of any of the preceding claims, wherein the method further comprises administering insulin to the subject.

19. The method of claim 18, wherein the insulin is administered to the subject separately from the composition comprising exosomes isolated from human adipose-derived stem cells .

20. The method of any of the preceding claims, wherein the composition further comprises insulin.

21. The method of any of claims 3 to 9, wherein the subject has been diagnosed with Parkinson’s disease or is a risk for developing Parkinson’s disease.